Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2025-08-29 Environmental & Social …
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
General Updates
Environmental & Social Information Classification · 100% confidence The document is titled 'Business Responsibility & Sustainability Report for F.Y. 2024-25' and references compliance with SEBI regulations. It contains detailed disclosures on environmental, social, and governance (ESG) factors, including employee data, product safety, innovation, grievance redressal, and sustainability issues. The content is consistent with a report detailing the company's performance on Environmental, Social, and Governance factors rather than financial results or corporate governance structure. The length of the document (15,000 characters) and the detailed nature of the disclosures confirm it is the report itself, not just an announcement. Therefore, the document fits the category of Environmental & Social Information (SR).
2025-08-29 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a detailed notice convening the 47th Annual General Meeting (AGM) of Glenmark Pharmaceuticals Limited for the financial year 2024-25. It includes the agenda items such as approval of audited financial statements, dividend declaration, appointment of directors and auditors, and other resolutions to be passed at the AGM. The document references the date and mode of the AGM (video conferencing), dividend record date, and compliance with SEBI and MCA regulations. It is not the actual annual report or financial statements but the official notice and explanatory statement for the AGM. Therefore, this document fits the category of AGM Information (AGM-R).
2025-08-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the transcript of an earnings call for the first quarter ended June 30, 2025. It references the SEBI (LODR) Regulations and provides a link to the transcript hosted on the company's website. The document itself does not contain the transcript but announces its availability and requests the exchanges to take it on record. The document length is short (1642 characters), and it is clearly an announcement of the transcript rather than the transcript itself. According to the classification rules, a full text transcript of a company conference call is classified as Call Transcript (CT). However, since this document is only an announcement of the transcript's availability and not the transcript itself, it should be classified as Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not fit other categories.
2025-08-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the schedule of upcoming analyst and institutional investor meetings. It explicitly states the dates, venues, and types of meetings planned. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory filings beyond the meeting schedule. The document is an announcement of investor meetings, which falls under the category of Capital/Financing Update (CAP) as it relates to investor relations and company communications about capital market activities. The document length is short (2005 characters), and it is not a report or certification, so it is not RPA or RNS. Therefore, the best classification is CAP with high confidence.
2025-08-28 English
Updates
Notice of Dividend Amount Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the closure of the register of members and share transfer books for a specific period. It mentions the purpose is for the upcoming 47th Annual General Meeting and to determine shareholders eligible for dividend payment if declared. The document references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 42, which pertains to book closure announcements. The document length is short (1663 characters) and does not contain any financial data, detailed report, or results. It is an announcement related to administrative procedures for the AGM and dividend eligibility, not the AGM materials themselves or the dividend declaration. Therefore, it fits best under the category of Notice of Dividend Amount (DIV) because it relates to dividend payment determination linked to the AGM, or possibly Regulatory Filings (RNS). However, since it specifically mentions book closure for dividend determination, the most appropriate classification is Notice of Dividend Amount (DIV).
2025-08-22 English
General Updates
Major Shareholding Notification Classification · 95% confidence The document is a letter addressed to the stock exchange listing departments, providing an update on the acquisition of securities in a private company (O2 Renewable Energy XXIV Private Limited). It references prior intimation and compliance with SEBI regulations regarding disclosure of such acquisitions. The content focuses on investment and shareholding updates rather than financial results, management changes, or regulatory certifications. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS. Therefore, the correct classification is MRQ with high confidence.
2025-08-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.